CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ARWR, mapped to public ticker ARWR (CIK 0000879407). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingARWR35% conf

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →